Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 2
2025 pubmed

LL-37 Attenuates Sepsis-Induced Lung Injury by Alleviating Inflammatory Response and Epithelial Cell Oxidative Injury via ZBP1-Mediated Autophagy.

Gao. Hu H; Tang. Fajuan F; Chen. Bin B; Li. Xihong X

Key Findings

  • LL‑37 reduced oxidative stress markers and cell death in lung epithelial cells exposed to bacterial toxin LPS
  • LL‑37 lowered pro‑inflammatory cytokines (IL‑18, TNF‑α, IL‑1β) in the same cells
  • LL‑37 restored autophagy that was blocked by LPS, and this effect depended on suppressing ZBP1
  • In a mouse sepsis model, LL‑37 improved lung tissue health, oxygenation, and blood sugar levels, effects reversed when ZBP1 was re‑activated

Practical Outcomes

  • The study shows LL‑37 has promise as a treatment for sepsis‑related lung injury, but it’s still early‑stage animal work. It isn’t ready for DIY use, and the peptide isn’t commercially available for humans. Biohackers can note the importance of autophagy and ZBP1 pathways for lung health, but should wait for clinical trials before considering any supplementation.

Summary

In mouse and cell experiments, the natural peptide LL‑37 helped protect lung cells from the damage caused by sepsis by cutting down inflammation, oxidative stress, and cell death, mainly through turning on a cleanup process called autophagy and lowering a protein called ZBP1.

Abstract

<b>Background:</b> Sepsis-induced acute lung injury (ALI) is a serious disease constituting a heavy burden on society due to high mortality and morbidity. Inflammation and oxidative stress constitute key pathological mechanisms in ALI caused by sepsis. LL-37 can improve the survival of septic mice. Nevertheless, its function and underlying mechanism in sepsis-evoked ALI is elusive. <b>Methods:</b> The human A549 alveolar epithelial cell line was treated with LL-37 or ZBP1 recombinant vector under LPS exposure. Then, the effects on cell oxidative stress injury, inflammatory response, and autophagy were analyzed. RNA-seq analysis was performed to detect the differentially expressed genes (DEGs) between the LPS and LPS/LL-37 groups. Furthermore, the effects of LL-37 on cecal ligation and the puncture (CLP)-constructed ALI model were explored. <b>Results:</b> LL-37 attenuated LPS-evoked oxidative injury in human alveolar epithelial cells by increasing cell viability and suppressing ROS, malondialdehyde, and lactate dehydrogenase levels and apoptosis. Moreover, LPS-induced releases of pro-inflammatory IL-18, TNF-&#x3b1;, and IL-1&#x3b2; were suppressed by LL-37. Furthermore, LPS's impairment of autophagy was reversed by LL-37. RNA-seq analysis substantiated 1350 differentially expressed genes between the LPS and LPS/LL-37 groups. Among them was ZBP1, a significantly down-regulated gene with the largest fold change. Moreover, LL-37 suppressed LPS-increased ZBP1 expression. Importantly, ZBP1 elevation restrained LL-37-induced autophagy in LPS-treated cells and abrogated LL-37-mediated protection against LPS-evoked oxidative injury and inflammation. LL-37 ameliorated abnormal histopathological changes, tissue edema, the lung injury score, oxygenation index (PaO2/FiO2), and glycemia contents in the CLP-constructed ALI model, which were offset through ZBP1 elevation via its activator CBL0137. Additionally, LL-37 suppressed inflammation and oxidative stress in lung tissues, concomitant with autophagy elevation and ZBP1 down-regulation. <b>Conclusions:</b> LL-37 may alleviate the progression of sepsis-evoked ALI by attenuating pulmonary epithelial cell oxidative injury and inflammatory response via ZBP1-mediated autophagy activation, indicating a promising approach for the therapy of ALI patients.

Study Information

Provider

pubmed

Year

2025

Date

2025-06-17T00:00:00.000Z

DOI

10.3390/toxins17060306

References

30